{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:02:37Z","timestamp":1761919357344},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T00:00:00Z","timestamp":1283212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9669-y","type":"journal-article","created":{"date-parts":[[2010,8,30]],"date-time":"2010-08-30T14:52:12Z","timestamp":1283179932000},"page":"165-168","source":"Crossref","is-referenced-by-count":21,"title":["Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report"],"prefix":"10.1007","volume":"28","author":[{"given":"Leonidas","family":"Chelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Napoleon","family":"Ntinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Souftas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savas","family":"Deftereos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Xenidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elen","family":"Chamalidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eustratios","family":"Maltezos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Kakolyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"9669_CR1","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1053\/j.gastro.2004.09.045","volume":"127","author":"AS Lok","year":"2004","unstructured":"Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127:S303\u20139.","journal-title":"Gastroenterology"},{"issue":"11","key":"9669_CR2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3748\/wjg.14.1657","volume":"14","author":"DC MacDonald","year":"2008","unstructured":"MacDonald DC, Nelson M, Bower M, Powles T, et al. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol. 2008;14(11):1657\u201363.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"9669_CR3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350901400207","volume":"14","author":"D Iser","year":"2009","unstructured":"Iser D, Lewin S. The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection. Antivir Ther. 2009;14(2):155\u201364.","journal-title":"Antivir Ther"},{"key":"9669_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","volume":"300","author":"K Bhaskaran","year":"2008","unstructured":"Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconvertion compared with mortality in the general population. JAMA. 2008;300:51\u20139.","journal-title":"JAMA"},{"key":"9669_CR5","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","volume":"166","author":"R Weber","year":"2006","unstructured":"Weber R, Sabin CA, Friis-Moller N, et al. Liver-relared deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632\u201341.","journal-title":"Arch Intern Med"},{"key":"9669_CR6","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e32831103ad","volume":"22","author":"GM Clifford","year":"2008","unstructured":"Clifford GM, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008;22:2135\u201341.","journal-title":"AIDS"},{"key":"9669_CR7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jhep.2008.11.018","volume":"50","author":"D Salmon-Ceron","year":"2009","unstructured":"Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of death in HIV-infected patients The French national Mortalit\u00e8 2005 study. J Hepatology. 2009;50:739\u201345.","journal-title":"J Hepatology"},{"key":"9669_CR8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208\u201336.","journal-title":"Hepatology"},{"key":"9669_CR9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"9669_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"issue":"2","key":"9669_CR11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1634\/theoncologist.2010-0010","volume":"15","author":"G Perboni","year":"2010","unstructured":"Perboni G, Costa P, Fibbia GC, et al. Sorafenib therapy for Hepatocellular carcinoma in an HIV-HCV Coinfectd Patient: A Case report. The Oncologist. 2010;15(2):142\u20135. Epub 2010 Feb 8.","journal-title":"The Oncologist"},{"key":"9669_CR12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-1-18","volume":"1","author":"BJ So","year":"2008","unstructured":"So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. Journal of Hematology & Oncology. 2008;1:18.","journal-title":"Journal of Hematology & Oncology"},{"key":"9669_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","volume":"10","author":"WA Chow","year":"2009","unstructured":"Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 2009;10:61\u201371.","journal-title":"Lancet Oncol"},{"key":"9669_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-8-26","volume":"8","author":"S Kumar","year":"2009","unstructured":"Kumar S, Bryant CS, Chamala S, et al. Ritonavir blocks AKT signalling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer. 2009;8:26.","journal-title":"Mol Cancer"},{"key":"9669_CR15","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-05-1167","volume":"12","author":"A Srirangam","year":"2006","unstructured":"Srirangam A, Mitra R, Wang M, et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res. 2006;12:1883\u201396.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9669_CR16","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","volume":"135","author":"A Villanueva","year":"2008","unstructured":"Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signalling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972\u201383.","journal-title":"Gastroenterology"},{"issue":"2","key":"9669_CR17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-09-2084","volume":"16","author":"RS Finn","year":"2010","unstructured":"Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res. 2010;16(2):390\u20137. Epub 2010 Jan 12.","journal-title":"Clin Cancer Res"},{"key":"9669_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-9-19","volume":"9","author":"A Br\u00fcning","year":"2010","unstructured":"Br\u00fcning A, Rahmeh M, Gingelmaier A, Friese K. The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. Mol Cancer. 2010;9:19.","journal-title":"Mol Cancer"},{"key":"9669_CR19","doi-asserted-by":"crossref","unstructured":"Br\u00fcning A, Burger P, Vogel M, Gingelmaier A, Friese K, Burges A. Nelfinavir induces mitochondria protection by ERK1\/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs;2009.","DOI":"10.1007\/s10637-009-9281-1"},{"issue":"1","key":"9669_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.antiviral.2009.10.021","volume":"85","author":"V Soriano","year":"2010","unstructured":"Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV co-infection. Antiviral Res. 2010;85(1):303\u201315.","journal-title":"Antiviral Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9669-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9669-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T02:10:47Z","timestamp":1685758247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9669-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":20,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9669"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9669-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}